PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
3.86%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
-1.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.77%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.49%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
16.41%
Share count expansion well above AVXL's 7.52%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.29%
Diluted share count expanding well above AVXL's 7.52%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
23.86%
OCF growth 1.25-1.5x AVXL's 16.21%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
23.57%
FCF growth 1.25-1.5x AVXL's 16.21%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19211.55%
Negative 5Y OCF/share CAGR while AVXL is at 65.86%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.46%
Negative 3Y OCF/share CAGR while AVXL stands at 6.13%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-50766.69%
Negative 5Y net income/share CAGR while AVXL is 22.57%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
48.21%
3Y net income/share CAGR similar to AVXL's 46.82%. Walter Schloss would attribute it to shared growth factors or demand patterns.
19776.75%
10Y equity/share CAGR above 1.5x AVXL's 5184.42%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
4394.26%
5Y equity/share CAGR above 1.5x AVXL's 193.33%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
625.15%
3Y equity/share CAGR above 1.5x AVXL's 162.51%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.68%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Our R&D shrinks while AVXL invests at 373.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
108.24%
SG&A growth well above AVXL's 63.03%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.